Until no far past, advanced hepatocellular carcinoma (HCC) was considered as an “orphan”
disease in terms of effective molecules when compared with other highly prevalent cancers …

Despite the successful approval and extensive application of sorafenib, the prognosis for
patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there …

Abstract According to the International Agency for Research on Cancer, approximately
670,000 new cases of hepatocellular carcinoma (HCC) developed in 2005, making it the fifth …

Importance of the field: With the recent advances in the knowledge of molecular biology of
hepatocellular carcinoma (HCC), there have been encouraging developments in targeted …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its
incidence is still increasing. While the primary curative treatment for HCC is surgical …

Hepatocellular carcinoma (HCC) is an aggressive tumor and the sixth most common form of
cancer worldwide. Surgery is the gold-standard treatment for local disease and often …

The advent of sorafenib can be considered as a turning point in the history of advanced
hepatocellular carcinoma. After unfortunate attempts at using chemotherapy, drugs targeting …

Importance of the field: The multikinase inhibitor sorafenib was the first agent to demonstrate
a survival benefit for patients with locally advanced or metastatic hepatocellular carcinoma …

Hepatocellular carcinoma (HCC), once considered an orphan disease in the West, has
become a global health concern. It is the third leading cause of cancer death worldwide, and …

Hepatocellular carcinoma (HCC) is one of the world's most common and deadly cancers.
Less than one-third of patients can currently benefit from potentially curative therapies in the …